Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.

Preclinical Evidence for the Use of Brexpiprazole + Antidepressant Treatment for Major Depressive Disorder and Post-Traumatic Stress Disorder: A Systematic Review

Open access
Brubaker, Malaak, Kapadia, Shivani, Maletic, Vladimir, Chambers, Jessie, Watling, Christopher, Citrome, Leslie · 2025 · Neuropsychiatric Disease and Treatment

Abstract

Purpose: Brexpiprazole, when administered with antidepressant therapy, may provide additional benefits due to complementary actions on noradrenaline (norepinephrine), serotonin, and dopamine neurotransmitter systems. This review addressed the question: what information can preclinical studies provide on the use of brexpiprazole + antidepressant treatment? Methods: A systematic literature review was conducted to search for preclinical studies of brexpiprazole + antidepressant therapy that included a behavioral test relating to any psychiatric disorder. Ovid MEDLINE, Ovid Embase, and conference abstracts were searched (January 1, 2011–July 5, 2021). The statistically significant (p< 0.05) findings for brexpiprazole + antidepressant were extracted. Results: Of 296 records screened, nine articles were eligible, describing seven unique studies. In rodent models, including three models of depression (unpredictable chronic mild stress, social defeat stress, and lipopolysaccharide-induced depression), brexpiprazole + selective serotonin reuptake inhibitor (SSRI) or serotonin–noradrenaline reuptake inhibitor (SNRI) consistently showed statistically significant benefits over vehicle on depression-like behaviors (forced swim test, tail suspension test, sucrose preference), whereas brexpiprazole and antidepressant monotherapies did not. In the predator scent stress model of post-traumatic stress disorder (PTSD), brexpiprazole + SSRI (escitalopram) showed a significant benefit over vehicle and/or monotherapy on anxiety-like behaviors (elevated plus-maze) and hyperalertness (acoustic startle response), whereas brexpiprazole and escitalopram monotherapies did not significantly differ from vehicle. In the fear conditioning model of PTSD, brexpiprazole showed significant improvements whether administered as monotherapy or in combination with escitalopram. Conclusion: Based on a small number of studies, the administration of brexpiprazole with an antidepressant appears to have a greater treatment effect than either brexpiprazole or antidepressant monotherapies in preclinical studies of depression- and PTSD-like behaviors. Thus, preclinical studies support evidence from randomized clinical trials for the therapeutic effects of adjunctive brexpiprazole in the treatment of major depressive disorder, and brexpiprazole in combination with sertraline in the treatment of PTSD. Funding: Otsuka/Lundbeck. Plain Language Summary: Studies of medications in animals can provide additional information to complement studies in humans. This review investigates what can be learned from animal studies of brexpiprazole (a medication known as an “atypical antipsychotic”) given together with an antidepressant medication. Seven animal studies that assess brexpiprazole + antidepressant treatment in rat or mouse models of depression and post-traumatic stress disorder were identified. Overall, these animal studies provide support for the observed benefits of brexpiprazole added to antidepressant treatment in major depressive disorder, and the ongoing development of brexpiprazole + antidepressant as a potential combination treatment for post-traumatic stress disorder. Keywords: antidepressants, antipsychotics, depression, PTSD, behavior rating scale

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ndt.s501207

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PRISMA flow diagram.
Figure 1 PRISMA flow diagram.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 98 references

Research works printed but not linked: 7

  1. 2013, Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
  2. Hitzemann, 2000, Alcohol Res Health, 24, 149
  3. Maeda K, Stensbøl TB, Akazawa H, et al. Pharmacological profile of brexpiprazole (OPC-34712): a novel serotonin–dopamine activity modulator. Poster presented at: American Psychiatric Association 167th Annual Meeting; 2014; New York, NY. Available from: https://www.psychiatry.org/Psychiatrists/Search-Directories-Databases/Conference-Publications/2014/2014-Annual-Meeting-Posters-New-Research-Abstracts. Accessed August 3, 2024.
  4. Lerdrup L, Maeda K, Stensbøl TB. Brexpiprazole shows antidepressant- and anxiolytic-like effects in the rat forced swim and Vogel conflict tests. Poster presented at: American Psychiatric Association 168th Annual Meeting; 2015; Toronto, Canada. Available from: https://www.psychiatry.org/Psychiatrists/Search-Directories-Databases/Conference-Publications/2015/2015-Annual-Meeting-Posters-New-Research-Abstracts. Accessed August 3, 2024.
  5. Porsolt, 1977, Arch Int Pharmacodyn Ther, 229, 327
  6. 2009, Methods of Behavior Analysis in Neuroscience
  7. 2015, Fluoxetine: Pharmacology, Mechanisms of Action and Potential Side Effects

Cited by

See all 7

Metadata

Authors
Brubaker, M., Kapadia, S., Maletic, V., Chambers, J., Watling, C., & Citrome, L.
Affiliations
  • Otsuka (United States) (US)
  • University of South Carolina (US)
  • New York Medical College (US)
Corresponding author
Brubaker, Malaak
Venue
Neuropsychiatric Disease and Treatment
Published
2025-02
Volume
Volume 21
Pages
421-436
ISSN
  • 1176-6328 (ISSN-L)
  • 1178-2021
OpenAlex
W4408033871
Cited by
7
References
98
Citations by year
2026: 4 · 2025: 3
FWCI
0.95
Type
journal article
Language
en
Open access
Locations
  • Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (acceptedVersion, other-oa)
  • Touro Scholar (Touro College) (submittedVersion, cc-by-nc)
Funders
  • Otsuka Pharmaceutical
  • H. Lundbeck A/S
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
brexpiprazole, major depressive disorder, post-traumatic stress disorder, antidepressant combination therapy, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, escitalopram, sertraline, rodent models of depression, social defeat stress, chronic unpredictable mild stress, lipopolysaccharide-induced depression, fear conditioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Evidence for the Use of Brexpiprazole + Antidepressant Treatment for Major Depressive Disorder and Post-Traumatic Stress Disorder: A Systematic Review. https://app.cochat.ai/papers/10.2147/ndt.s501207
The paper
Brubaker, M., Kapadia, S., Maletic, V., Chambers, J., Watling, C., & Citrome, L. (2025). Preclinical Evidence for the Use of Brexpiprazole + Antidepressant Treatment for Major Depressive Disorder and Post-Traumatic Stress Disorder: A Systematic Review. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s501207

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.